CN115667312A - 抗muc1-sea抗体 - Google Patents

抗muc1-sea抗体 Download PDF

Info

Publication number
CN115667312A
CN115667312A CN202180021191.8A CN202180021191A CN115667312A CN 115667312 A CN115667312 A CN 115667312A CN 202180021191 A CN202180021191 A CN 202180021191A CN 115667312 A CN115667312 A CN 115667312A
Authority
CN
China
Prior art keywords
seq
represented
acid sequence
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180021191.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·鲁宾斯坦
D·雷舒纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Biomodification Co ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Biomodification Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Biomodification Co ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CN115667312A publication Critical patent/CN115667312A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
CN202180021191.8A 2020-03-18 2021-03-11 抗muc1-sea抗体 Pending CN115667312A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991077P 2020-03-18 2020-03-18
US62/991,077 2020-03-18
PCT/IL2021/050269 WO2021186427A1 (en) 2020-03-18 2021-03-11 Anti- muc1-sea antibodies

Publications (1)

Publication Number Publication Date
CN115667312A true CN115667312A (zh) 2023-01-31

Family

ID=75439163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180021191.8A Pending CN115667312A (zh) 2020-03-18 2021-03-11 抗muc1-sea抗体

Country Status (20)

Country Link
US (1) US20230085269A1 (enExample)
EP (1) EP4087879A1 (enExample)
JP (1) JP2023517754A (enExample)
KR (1) KR20220161267A (enExample)
CN (1) CN115667312A (enExample)
AU (1) AU2021239078A1 (enExample)
BR (1) BR112022018629A2 (enExample)
CA (1) CA3171531A1 (enExample)
CL (1) CL2022002520A1 (enExample)
CO (1) CO2022014726A2 (enExample)
CR (1) CR20220523A (enExample)
CU (1) CU20220055A7 (enExample)
DO (1) DOP2022000193A (enExample)
EC (1) ECSP22080687A (enExample)
IL (1) IL296572A (enExample)
MX (1) MX2022011553A (enExample)
PE (1) PE20230602A1 (enExample)
PH (1) PH12022552445A1 (enExample)
WO (1) WO2021186427A1 (enExample)
ZA (1) ZA202211303B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120936627A (zh) * 2023-03-03 2025-11-11 广州百济神州生物制药有限公司 Muc1抗体及使用方法
WO2024183635A1 (en) * 2023-03-03 2024-09-12 Beigene, Ltd. Muc1 and cd16a antibodies and methods of use
US20250041437A1 (en) 2023-07-31 2025-02-06 Sun Pharma Advanced Research Company Limited Humanized muc1 antibody and antibody drug conjugate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081553A2 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. ANTI-MUC1 α/ß ANTIBODIES
CN102459335A (zh) * 2009-04-17 2012-05-16 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
US20160311927A1 (en) * 2013-12-19 2016-10-27 Arocell Ab Monoclonal anti-tk1 antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
IL269488B2 (en) * 2017-03-21 2023-09-01 Peptron Inc Conjugation of an antibody specifically for muc1 and its use
WO2018174544A2 (ko) * 2017-03-21 2018-09-27 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
WO2019094626A1 (en) * 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081553A2 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. ANTI-MUC1 α/ß ANTIBODIES
CN102459335A (zh) * 2009-04-17 2012-05-16 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
US20160311927A1 (en) * 2013-12-19 2016-10-27 Arocell Ab Monoclonal anti-tk1 antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EDWARD PICHINUK 等: ""Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells"", 《CANCER RES》, vol. 72, no. 13, 16 April 2012 (2012-04-16) *
EDWARD PICHINUK 等: ""In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies"", 《CANCER IMMUNOL IMMUNOTHER .》, vol. 69, no. 7, 26 March 2020 (2020-03-26), pages 1337 - 1352, XP037168525, DOI: 10.1007/s00262-020-02547-2 *
LEVY, N.S.等: ""RecName: Full=Ig heavy chain V region 1B43; Flags: Precursor"", 《GENBANK》, 7 November 2018 (2018-11-07), pages 18532 *

Also Published As

Publication number Publication date
MX2022011553A (es) 2023-01-04
ECSP22080687A (es) 2022-12-30
US20230085269A1 (en) 2023-03-16
KR20220161267A (ko) 2022-12-06
AU2021239078A1 (en) 2022-08-11
CA3171531A1 (en) 2021-09-23
DOP2022000193A (es) 2023-03-23
IL296572A (en) 2022-11-01
EP4087879A1 (en) 2022-11-16
PH12022552445A1 (en) 2023-11-20
WO2021186427A1 (en) 2021-09-23
PE20230602A1 (es) 2023-04-10
CO2022014726A2 (es) 2023-02-16
BR112022018629A2 (pt) 2023-03-07
CL2022002520A1 (es) 2023-03-10
ZA202211303B (en) 2025-08-27
CR20220523A (es) 2023-01-23
JP2023517754A (ja) 2023-04-26
CU20220055A7 (es) 2023-06-13

Similar Documents

Publication Publication Date Title
CN113166246B (zh) 一种抗体及其用途
CN112154157B (zh) 抗ror1抗体及其用途
EP3353213B1 (en) Anti-mesothelin antibody and composition comprising the same
AU2009201674B2 (en) Novel anti-IGF-IR antibodies and uses thereof
CN114514246A (zh) 对nectin-4具有特异性的抗体及其用途
CN113330034A (zh) 针对B7-H3的IgV结构域的单克隆抗体及其用途
US20100278818A1 (en) Antibody specific for the Tn antigen for the treatment of cancer
CN104220094A (zh) 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
CN110240655A (zh) 抗her2抗体及其缀合物
TWI876253B (zh) Nectin細胞黏附分子4之特異性抗體及其用途
CN115667312A (zh) 抗muc1-sea抗体
WO2022117050A1 (zh) 一种新型肿瘤衔接器治疗药物的开发和应用
CN108137695B (zh) 作为功能性癌症靶标的、不在糖脂而在糖蛋白上表达的唾液酸化二路易斯a及其抗体
CN117425500A (zh) 抗dll3抗体-药物缀合物
CN116507641A (zh) 结合素-4抗体及其用途
CN117425501A (zh) 抗体-吡咯并苯二氮䓬衍生物缀合物
EA049289B1 (ru) Антитела к sea-muc1
OA20958A (en) Anti- MUC1-sea antibodies
WO2024012395A1 (en) Anti-mesothelin antibodies
KR101996627B1 (ko) Vcam-1-d6에 결합하는 항체 및 그 용도
CN120329439A (zh) 一种单克隆抗体及其应用
HK40048164B (zh) 一种抗体及其用途
IL285313A (en) Antibodies for cancer treatment
CN117597362A (zh) 抗紧密连接蛋白-6的抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination